This study evaluated the receptor-and/or antioxidant stress-mediated mechanisms by which melatonin prevents the ovarian toxicity of cisplatin treatment. The expression of the MT 1 receptor in mouse ovaries was investigated by immunohistochemistry. Pretreatment with melatonin (5, 10, or 20 mg/kg body weight, i.p.) before cisplatin (5 mg/kg body weight, i.p.) was administered to mice once daily for 3 days (phase I). The pharmacological modulation via melatonin type 1 and/or 2 receptors was analyzed by administration of receptor antagonists (luzindole: nonselective MT 1 /MT 2 antagonist; 5 mg/kg body weight or 4-phenyl-2-propionamidotetralin: selective MT 2 antagonist; 4 mg/kg body weight) once daily for 3 days, 15 min before the treatment with melatonin and cisplatin (phase II). Thereafter, the ovaries were harvested and used for histological (morphology and activation), immunohistochemical (PCNA, activated caspase-3 and bcl-2 expression), terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, and fluorescence (reactive oxygen species [ROS], glutathione [GSH], and active mitochondria levels) analyses. The expression of the MT 1 protein in mouse ovaries was documented. Pretreatment with 20 mg/kg melatonin before cisplatin administration preserved the normal follicular morphology and cell proliferation rate, reduced apoptosis, ROS production, mitochondrial damage and increased GSH expression, as compared to the cisplatin treatment alone. Additionally, administration of the nonselective MT 1 /MT 2 receptor antagonist inhibited the melatonin ovarian protection from the cytotoxic effects of cisplatin. However, administration of a selective MT 2 antagonist did not modify the protective effects observed at 20 mg/kg melatonin. In conclusion, pretreatment with 20 mg/kg melatonin effectively protected the ovaries against cisplatin-induced damage. Moreover, the MT 1 receptor and melatonin antioxidant effects mediated this cytoprotective activity. Melatonin and ovarian preservation, 2017, Vol. 96, No. 6 
Introduction

Cisplatin
(cis-diamminedichloroplatinum-II), an alkylating chemotherapeutic agent, is a first-line agent for ovarian cancer treatment [1] . It acts by inducing the formation of interstrand and intrastrand DNA adducts [2, 3] . However, treatment with cisplatin is associated with numerous side effects, including reproductive toxicity [4, 5] . For women of reproductive age, cisplatin-induced gonadotoxicity may cause changes in the menstrual cycle and loss of primordial follicles by apoptosis, resulting in the depletion of the ovarian reserve and consequent premature ovarian failure [6, 7] , by increasing reactive oxygen species (ROS) production, decreasing antioxidant capacity, and increasing damage to the mitochondria and DNA [8] [9] [10] . To overcome these side effects, the administration of an antioxidant during chemotherapy may prevent the toxic effects of cisplatin on ovarian function [11, 12] . Melatonin is one of the most active antioxidants available.
Melatonin (N-acetyl-5-methoxytryptamine) was first discovered as a secretory product of the vertebrate pineal gland, regulating some important central and peripheral actions related to circadian rhythms, behavior, immune response, and reproductive function [13, 14] . However, this hormone is synthesized in a variety of tissues including peripheral tissues such as the gastrointestinal tract, skin, leukocytes, bone marrow, placenta, and ovary [14] [15] [16] . In these tissues, melatonin actions can be mediated through interaction with its receptors type 1 (MT 1 ) and type 2 (MT 2 ), which are G-protein-coupled membrane-bound receptors [17] . Studies support the hypothesis that the MT 1 receptor may be more involved in the regulation of reproductive activity than the MT 2 [18, 19] . In the mouse ovary, RT-PCR analysis revealed the expression of MT 1 mRNA in granulosa cells from the primary follicle stage onward [20] . Although MT 1 receptors may be a viable target for novel agents capable of counteracting the oxidative stress components of cisplatin-induced toxicity, there is no data on the immunolocalization of the MT 1 protein, in the different follicular stages of mouse ovaries.
Melatonin exerts its effect through its receptors and it can also act as a potent ROS scavenger [21, 22] , by increasing glutathione (GSH) levels and other antioxidant enzymes [23, 24] . Moreover, melatonin could enhance the anticancer effect of cisplatin in breast cancer and reduce its side effects [25] [26] [27] . It has also been reported that the use of melatonin during chemotherapy prevents cisplatin-induced testis and kidney toxicity [5, 28] . In addition, melatonin reduced cisplatin-induced mouse primordial follicle loss by inhibiting the phosphorylation of PTEN/AKT/FOXO3a pathway members [11] . In latter study, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) analysis showed that cisplatin does not induce the DNA fragmentation of primordial follicles, but melatonin prevented cisplatin-induced granulosa cell apoptosis in growing follicles. However, the specific mechanisms underlying the actions of melatonin protection against chemotherapy-induced ovarian follicle death have not yet been clearly understood. Therefore, it is still necessary to evaluate whether the main effect of melatonin involves the receptor pathway, which could influence the maintenance of follicle morphology and growth, and/or an effect on oxidative stress response by influencing ROS and GSH production, mitochondrial activity, and apoptosis in follicular cells.
Therefore, the objectives of this study were (i) to characterize protein expression for MT 1 protein in mouse ovaries; (ii) to evaluate whether pretreatment with melatonin before cisplatin administration could preserve mouse normal ovarian follicle morphology, and affect primordial follicle activation, cell proliferation, apoptosis, oxidative stress markers (ROS and GSH levels), and metabolically active mitochondria; and (iii) to evaluate if the possible cytoprotective effects of melatonin are mediated through MT 1 and/or MT 2 receptors.
Materials and methods
Animals
This study was conducted according to the ethical guidelines of the Ethics Committee on Animal Use, at the Federal University of São Francisco Valley (protocol number 0005/10516). Adult female Swiss mice (n = 45), aged 8 weeks and weighing between 30 and 45 g, were housed in an air-conditioned atmosphere, at a temperature of 25
• C with alternating 12 h light and dark cycles. Animals were maintained on a standard diet and water was administered ad libitum.
Immunohistochemical localization of MT 1 in mouse ovary
Immunohistochemistry was performed according to previous studies [29, 30] with some modifications. Ovaries (n = 10) from five mice were collected and fixed in 10% buffered formalin (Dinâmica, São Paulo, Brazil). After 18 h of fixation, the ovarian tissue was dehydrated with increasing concentrations of ethanol (Dinâmica), clarified in xylene (Dinâmica), and embedded in paraffin (Dinâmica). Sections (5 μm thick) from each block were cut using a microtome (EasyPath, São Paulo, Brazil) and mounted in Starfrost glass slides (Knittel, Braunschweig, Germany). The slides were incubated in citrate buffer (Dinâmica) at 95
• C in a deckloaking chamber (Biocare, Concord, USA) for 40 min to retrieve antigenicity, and endogenous peroxidase activity was prevented by incubation with 3% H 2 O 2 (Dinâmica) and methyl ethanol (QEEL, São Paulo, Brazil) for 10 min. Nonspecific binding sites were blocked using 1% normal goat serum (Biocare) and diluted in phosphate-buffered saline (PBS; Sigma Aldrich Chemical Co., St. Louis, MO, USA). Subsequently, the sections were incubated in a humidified chamber for 90 min at room temperature with polyclonal rabbit anti-MT 1 (1:30; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Thereafter, the sections were incubated for 30 min with MACH4 Universal HRP-polymer (Biocare). Protein localization was demonstrated with diaminobenzidine (DAB; Biocare), and the sections were counterstained with hematoxylin (Vetec, São Paulo, Brazil) for 1 min. Negative controls (reaction control) were performed in the absence of the rabbit polyclonal anti-MT 1 . A list of all antibodies used is shown in Supplemental Table S1 .
Follicles were classified based on the morphological criteria of Pedersen and Peters [31] as primordial (one layer of flattened or flattened and cuboidal granulosa cells), primary (a complete layer of cuboidal granulosa cells surrounding the oocyte), secondary (two or more cuboidal layers of granulosa cells and no sign of antrum formation), and antral (multiple granulosa cell layers with some antral space). In the different follicular compartments (oocyte, granulosa, and theca cells), the immunostaining was classified as absent, weak, moderate, or strong. The slides were examined using a light microscope (Nikon, Tokyo, Japan).
Experimental design (chemotherapy) Phase I: effect of different doses of melatonin on cisplatininduced acute ovarian toxicity
The mice (n = 25) were randomly divided into five experimental groups (five animals per group) and treated for 3 days as follows: the first group acting as a control received intraperitoneal injection (i.p.) of vehicle (ethanol 5% in NaCl 0.15 M, 0.15 ml/mouse), once daily, for 3 days. The second group received cisplatin (5 mg/kg body weight, i.p.; Libbs Farmacêutica Ltda, São Paulo, Brazil) at 30 min after vehicle treatment, once daily, for 3 days (total of 15 mg/kg of cisplatin). For the third, fourth, and fifth groups, mice received melatonin (Sigma Aldrich Chemical) at 5, 10, or 20 mg/kg body weight (i.p.), respectively, once daily, and after 30 min of melatonin injection, mice received cisplatin (5 mg/kg body weight, i.p.) once daily for 3 days (total of 15 mg/kg of cisplatin). The dose of cisplatin administered was tested in a pilot study from our laboratory and was found sufficient to induce a decline in the number of normal ovarian follicles. The dose of melatonin administered was based on previous studies showing its protective effects [32] [33] [34] . The ovaries were harvested from the mice 24 h after the last injection of melatonin, based on other studies related to the preclinical efficacy of melatonin to reduce chemotherapy-induced toxicity in rodent tissues [34] [35] [36] ; ovarian tissues were dissected, washed in PBS, and used for histological, immunohistochemical, TUNEL, and fluorescence analyses.
Phase II: effect of administration of melatonin receptor 1 and 2 (MT 1 and MT 2 ) antagonists before melatonin treatment on cisplatin-induced acute ovarian toxicity In order to suggest a possible mechanism for the protective effect of melatonin on cisplatin-induced ovarian damage, the pharmacological modulation via melatonin type 1 and/or 2 receptors was analyzed by administration of MT 1 and/or MT 2 antagonists. The first, second, and third groups were the control, cisplatin, cisplatin plus melatonin 20 mg/kg, which produced the best results, respectively. All these groups were described in phase I. For the fourth and fifth groups, mice (n = 10; five animals per group) were pretreated with luzindole (nonselective MT 1 /MT 2 antagonist; 5 mg/kg body weight, i.p.; Sigma Aldrich Chemical Co.) or 4-phenyl-2-propionamidotetralin(4-PPDOT; selective MT 2 antagonist; 4 mg/kg body weight, i.p.; Sigma Aldrich Chemical Co.), respectively. After 15 min, melatonin (20 mg/kg body weight, i.p.) was administered, and after 30 min of melatonin injection, cisplatin was administered to the mice (5 mg/kg body weight, i.p.). The combination of treatments was performed once daily for 3 days. A positive control (sixth group) was administered before cisplatin, using the antioxidant N-acetylcysteine 150 mg/kg body weight (i.p.), thereby replacing melatonin pretreatment. The doses of administration of melatonin antagonists and N-acetylcysteine have been studied by Chen et al. [37] and Anand et al. [38] , respectively. As described for phase I, the mice were sacrificed 24 h after the last injection; ovarian tissues were dissected, washed in PBS, and used for analysis.
Morphological analysis and assessment of follicular activation
For morphological examination, the ovaries (one ovary per animal) were fixed in 10% buffered formalin (Dinâmica) overnight, dehydrated using graded ethanol (Dinâmica), clarified in xylene (Dinâmica), and embedded in paraffin (Dinâmica). Hematoxylin and eosin (Vetec) was used to stain 5-μm thick serial sections, for routine histological examination, under a light microscope (Nikon). Follicles were classified based on the Pedersen and Peters [31] morphological criteria, as described previously, in primordial, primary, secondary, and antral follicles. In addition, these follicles were classified individually as histologically normal, when an intact oocyte was present and surrounded by granulosa cells that were well organized in one or more layers and had no pyknotic nuclei. Atretic follicles were defined as those with a retracted or vacuolated oocyte, pyknotic nucleus, disorganized granulosa cells detached from the basement membrane, or cell swelling. To avoid double counting of the same follicles, a follicle was counted on the first section in which the centrally located nucleus of the oocyte appeared.
To evaluate follicular activation (transition from primordial to primary follicles), only morphologically normal follicles with a visible oocyte nucleus were recorded, and the proportion of primordial and growing (primary, secondary, and antral) follicles was calculated in different treatments. Overall, 150 follicles were evaluated for each treatment (30 follicles per treatment × five replicates = 150 follicles) according to Faustino et al. [39] .
Immunohistochemistry
Immunohistochemical analysis was carried out by the same steps that were previously mentioned for the MT 1 assay, except for the antibodies used, which were (i) rabbit polyclonal anti-PCNA (a marker of cellular proliferation; 1:100; Santa Cruz Biotechnology), (ii) rabbit polyclonal anti-Bcl-2 (anti apoptotic protein; 1:30; Santa Cruz Biotechnology), and (iii) rabbit polyclonal anti-activated caspase-3 (pro apoptotic protein; 1:50; Santa Cruz Biotechnology).
Only follicles that contained an oocyte nucleus were analyzed for proliferating cell assay and apoptotic markers. Using the Image-Pro Plus R software, the number of PCNA-positive granulosa and theca cells (brown staining) was counted in 10 random fields per treatment. The percentage of PCNA-positive cells was calculated as the number of proliferating cells out of the total number of cells (×100). For Bcl-2 and activated caspase-3 expression, follicles (20 follicles for Bcl-2 and 20 follicles for activated caspase-3) in the different developmental stages (primordial, primary, secondary, and antral follicles) were evaluated in 10 random fields per treatment according to previous studies [40, 41] . The relative intensity of the immunostaining of activated caspase-3 and Bcl-2 proteins was measured by the Image J software program (Version 1.41; National Institutes of Health, Bethesda, MD, USA) after normalization by the amount of the respective total proteins.
Detection of DNA fragmentation by TUNEL assay
DNA fragmentation was assessed using the TUNEL assay. TUNEL assay was performed using a commercial kit (In Situ Cell Death Detection Kit, Roche Diagnostics Ltd, Indianapolis, USA) following the manufacturer's protocol, with some modifications. Briefly, Downloaded from https://academic.oup.com/biolreprod/article-abstract/96/6/1244/3862712 by OUP site access user on 15 October 2018 5-μm sections mounted in Starfrost glass slides (Knittel) were incubated in citrate buffer (Dinâmica) at 95
• C in a deckloaking chamber (Biocare) for 40 min to retrieve antigenicity, and endogenous peroxidase activity was prevented by incubation with 3% H 2 O 2 (Dinâmica) and methyl ethanol (QEEL) for 10 min. After rinsing in PBS (Sigma Aldrich Chemical Co.), the sections were incubated with the TUNEL reaction mixture at 37
• C for 1 h. Then, the specimens were incubated with Converter-POD in a humidified chamber at 37
• C for 30 min. DNA fragmentation was revealed by incubation of the tissues with DAB (Biocare) for 5 min. Finally, sections were counterstained with hematoxylin (Vetec) in a dark chamber at room temperature for 1 min, dehydrated in ethanol (Dinâmica), cleared in xylene (Dinâmica), and mounted with balsam (Dinâmica). For negative controls, slides were incubated with label solution (without terminal deoxynucleotidyl transferase enzyme) instead of the TUNEL reaction mixture. Only follicles that contained an oocyte nucleus were analyzed for TUNEL assay, according to Santos et al. [42] . The number of brown TUNEL-positive cells (oocyte and granulosa cells) was counted in 10 random fields per treatment, using the Image-Pro Plus R software. The percentage of TUNEL-positive cells was calculated as the number of TUNEL-positive cells out of the total number of cells (×100).
Measurement of intracellular levels of reactive oxygen species, glutathione, and mitochondrial activity by fluorescence
The intracellular levels of ROS, GSH, and mitochondrial activity were measured using already described methods [43, 44] . Briefly, 2', 7'-dichlorodihydrofluorescein diacetate (H2DCFDA; Invitrogen Corporation, Carlsbad, CA, USA), 4-chloromethyl-6.8-difluoro-7-hydroxycoumarin (CellTracker R Blue; CMF2HC; Invitrogen Corporation), and Mitotracker Red (Mitotracker R Red, CMXRos, Molecular Probes, Melbourne, Victoria, Australia) were used to detect the levels of ROS, GSH, and mitochondrial activity as green, blue, and red fluorescence, respectively. Follicles (n = 40 follicles in each treatment) in different stages of development (primordial, primary, secondary, and small antral follicles) were mechanically isolated using 26-G needles from the ovaries (one ovary per animal) and incubated in the dark for 30 min in PBS (Sigma Aldrich Chemical Co.) added with 10 μM H2DCFDA, 10 μM CellTracker Blue, and 100 nM Mitotracker Red. After incubation, the follicles were washed with PBS (Sigma Aldrich Chemical Co.) for 30 min and fluorescence was observed under an epifluorescence microscope (Nikon) with UV filters (460 nm for ROS, 370 nm for GSH, and 579 nm for active mitochondria). The fluorescence intensities were analyzed by using the Image J software (Version 1.41; National Institute of Health).
Statistical analysis
The percentages of morphologically normal follicles, primordial, and growing (primary, secondary, and antral follicles) and data from Bcl-2 and activated caspase-3 were submitted to ANOVA, and the Tukey test was applied for comparison among treatments. The values of PCNA and TUNEL-positive cells were submitted to the Chi-square test. Data from ROS, GSH, and mitochondrial activity were submitted to the Shapiro-Wilk test to verify the normal distribution of residuals and homogeneity of variances. Thereafter, the KruskalWallis nonparametric test was used for comparisons. When the main effects or interactions were significant, means were compared by the Dunn test. The results were expressed as the means ± standard error mean (SEM), and differences were considered significant when P < 0.05.
Results
Immunohistochemistry expression of MT 1 in mice ovary
Oocytes from primordial follicles ( Figure 1A) showed a weak reaction for MT 1 protein, while oocytes from primary ( Figure 1B) , secondary ( Figure 1C) , and antral ( Figure 1D ) follicles showed a moderate reaction. In the granulosa cells of primary follicles, a weak immunostaining was observed for MT 1 while a moderate expression was observed in the granulosa cells of secondary and antral follicles. Moreover, the theca cells of the secondary and antral follicles showed a weak reaction for the MT 1 protein. No staining was observed in the granulosa cells of the primordial follicles ( Figure 1A) , as well as in the negative control ( Figure 1E ).
Phase I: effect of different doses of melatonin on cisplatin-induced acute ovarian toxicity Follicular morphology, primordial follicle activation, and cell proliferation Mice from the control group showed normal ovarian morphology with centrally located oocytes and granulosa cells surrounded by normal intact basement membranes (Figure 2A) . However, the cisplatin group damaged the ovarian structure and promoted a reduction in the number of follicles ( Figure 2B ). The morphology of the ovarian tissue from animals pretreated with 5 ( Figure 2C ) or 10 ( Figure 2D ) mg/kg melatonin was not different from those in the cisplatin group. The latter three groups showed swollen and disorganized granulosa cells, retracted or vacuolated oocyte, and/or pyknotic nucleus. Pretreatment with 20 mg/kg melatonin decreased the follicular damage caused by cisplatin ( Figure 2E ), and the follicles showed morphological features similar to those of the control group.
Cisplatin treatment decreased (P < 0.05) the percentage of morphologically normal follicles (35%) in comparison to the control group (82%). Melatonin (20 mg/kg) pretreatment prevented (P < 0.05) a reduction in the percentage of normal follicles induced by cisplatin, which occurred neither in melatonin 5 mg/kg nor in melatonin 10 mg/kg pretreatments (26% and 37%, respectively; Figure 3A) . Figure 3B shows the percentage of morphologically normal follicles in different developmental stages. Cisplatin treatment decreased (P < 0.05) the percentage of normal follicles within each follicular category (primordial, primary, secondary, and antral), compared to the control. Melatonin (20 mg/kg) pretreatment prevented it (P < 0.05). However, other melatonin doses (5 or 10 mg/kg) showed rates of normal primordial, primary, and secondary follicles similar (P > 0.05) to the cisplatin group and lower (P < 0.05) than the control group. Primordial follicle activation was not observed in any treatment (P > 0.05). Moreover, mice treated with cisplatin alone showed a decrease (P < 0.05) in the percentage of PCNA-positive cells compared to the control or fifth group (20 mg/kg melatonin plus cisplatin). However, other melatonin doses (5 or 10 mg/kg) did not prevent (P > 0.05) this reduction in the percentage of PCNA-positive cells induced by cisplatin ( Figures 3C and 4A-D) . Table 1 shows the relative expression of Bcl-2 and activated caspase-3 in mice ovaries and the percentage of TUNEL-positive cells exposed to the different treatments. No change (P > 0.05) in Bcl-2 intensity was observed among the treatments (Table 1 ; see also Supplemental Figure S1 ). Cisplatin treatment increased the activated caspase-3 intensity (P < 0.05), compared to the control group. On the other hand, the highest activated caspase-3 intensity in the cisplatin group was reduced (P < 0.05) only with the 20 mg/kg melatonin pretreatment. No differences (P > 0.05) were observed between the control and the different melatonin doses, regarding the expression of activated caspase-3 (Table 1 and Figure 4E -G; see also Supplemental Figure S1 ).
Apoptosis markers
The ovarian tissue in the control group did not show or showed less cells with DNA damage (Figure 4H ). However, DNA fragmentation was commonly found in the cisplatin group ( Figure 4I ), which increased (P < 0.05) the percentage of TUNEL-positive oocytes, granulosa cells, and total ovarian cells (oocyte + granulosa) as compared to the control ( Table 1 ). The increase in TUNEL-positive cells was prevented (P < 0.05) with 20 mg/kg melatonin treatment (Table 1 and Figure 4J) . A negative control for the TUNEL reaction is shown in Figure 4K .
Intracellular levels of reactive oxygen species, glutathione, and mitochondrial activity Figure 5A and B shows that cisplatin treatment increased ROS levels and decreased GHS levels and mitochondrial activity in comparison to the control group. All melatonin doses reduced (P < 0.05) the ROS levels and increased (P < 0.05) the mitochondrial activity as compared to the cisplatin group. However, the GSH levels increased Figure 5 . Epifluorescent photomicrographic images of mice follicles stained with 2', 7' -dichlorodihydrofluorescein diacetate (a-h), CellTracker Blue (i-p), and MitoTracker Red (q-x) to detect intracellular levels of ROS, GSH, and mitochondrial function, respectively (A): follicles in the control group (a, i, q), exposed to cisplatin alone (b, j, r), exposed to 5 mg/kg (c, k, s), 10 mg/kg (d, l, t), or 20 mg/kg (e, m, u) melatonin plus cisplatin, exposed to MT1/MT2 antagonist (f, n, v) or MT2 antagonist (g, o, w), and exposed to N-acetylcysteine (h, p, x). Scale bars: 50 μm (×100). Intracellular levels of ROS, GSH, and mitochondrial function in mice follicles of different experimental groups exposed or not to cisplatin alone or in combination with different concentrations of melatonin (5, 10, (P < 0.05) only after pretreatment with 20 mg/kg melatonin before cisplatin administration, as compared to cisplatin alone. In addition, no differences (P > 0.05) were observed between the control and 20 mg/kg melatonin group for ROS and active mitochondria levels ( Figure 5A and B).
Phase II: effect of administration of melatonin receptor antagonists before melatonin treatment on cisplatin-induced acute ovarian toxicity Follicular morphology, primordial follicle activation, and cell proliferation Melatonin (20 mg/kg) prevented a reduction (P < 0.05) in the percentage of entirely morphological normal follicles and in the percentage of normal follicles within each follicular category (primordial, primary, secondary, and antral) induced by cisplatin. The protective effect of melatonin in the ovary was similar (P > 0.05) to that mediated by N-acetylcysteine, a recognized antioxidant agent previously used by others in mice, whose ovaries had been subjected to the cisplatin challenge ( Figure 6A and B) . Nevertheless, a nonselective MT 1 /MT 2 antagonist (luzindole) treatment inhibited (P < 0.05) this melatonin protection from the cytotoxic effects of cisplatin on morphologically normal follicles. On the other hand, a selective MT 2 antagonist (4-PPDOT) did not inhibit (P > 0.05) the protective activity of melatonin ( Figure 6A and B). Primordial follicle activation was not observed in any treatment (P > 0.05). Treatment with cisplatin decreased (P < 0.05) the percentage of PCNA-positive cells compared to the control, melatonin (20 mg/kg) plus cisplatin, selective MT 2 antagonist (4-PPDOT), and N-acetylcysteine groups. No differences (P > 0.05) were observed between nonselective MT 1 /MT 2 antagonists (luzindole) and other groups ( Figure 6C ).
Similar to phase I, no change (P > 0.05) in Bcl-2 intensity was observed among the treatment groups (Table 2) . However, the intensity of activated caspase-3 in cisplatin treatment was similar (P > 0.05) to the nonselective MT 1 /MT 2 antagonist (luzindole) and higher (P < 0.05) than other groups (Table 2 ). In addition, the percentage of TUNEL-positive cells (oocyte and/or granulosa cells) was higher (P < 0.05) in cisplatin and nonselective MT 1 /MT 2 antagonist (luzindole) treatments than other groups. There were no differences (P > 0.05) in the percentage of oocytes, granulosa cells, and total ovarian (oocyte + granulosa) cells among the control, Downloaded from https://academic.oup.com/biolreprod/article-abstract/96/6/1244/3862712 by OUP site access user on 15 October 2018 Figure 6 . Total follicular survival (percentage of morphologically normal follicles; A); percentage of morphologically normal follicles in different stages (primordial, primary, secondary and antral follicles; B) and percentage of PCNA-positive cells (proliferating cells; C) in the control group, mice exposed to cisplatin alone, exposed to 20 mg/kg melatonin before cisplatin, or exposed to MT1/MT2 melatonin receptor antagonist or MT2 antagonist before melatonin and cisplatin exposure, or exposed to N-acetylcysteine before cisplatin. ( a, b, c ) Bars with different letters are significantly different (P < 0.05). Table 2 . Relative expressions (intensity in pixel) of Bcl-2 and activated caspase-3 in mice ovaries and the percentage of TUNEL-positive oocytes, granulosa cells, and total ovarian cells (oocyte + granulosa) in different experimental groups (control: not exposed to cisplatin; exposed to cisplatin; pretreated with 20 mg/kg melatonin before cisplatin exposure; or exposed to MT 1 /MT 2 melatonin receptor antagonist or MT 2 antagonist before melatonin and cisplatin exposure; or exposed to N-acetylcysteine before cisplatin; phase II). 20 mg/kg melatonin, selective MT 2 antagonist (4-PPDOT), and Nacetylcysteine groups (Table 2 ).
Intracellular levels of reactive oxygen species, glutathione, and mitochondrial activity Figure 5A and C shows that cisplatin treatment increased the ROS levels but decreased the GHS levels and mitochondrial activity, in comparison to the control group. This oxidative stress was prevented (P < 0.05) by 20 mg/kg melatonin and N-acetylcysteine treatments. The effects of melatonin (20 mg/kg) on ROS levels and mitochondrial activity were blocked (P < 0.05) in animals pretreated with a nonselective MT 1 /MT 2 antagonist (luzindole). The selective MT 2 antagonist (4-PPDOT) did not block the melatonin protection of the ovary. Thus, in this group, the levels of ROS, GSH, and mitochondrial activity were similar (P > 0.05) to that of the 20 mg/kg melatonin group ( Figure 5A and C) .
Discussion
This study demonstrated that the melatonin treatment attenuated the cisplatin-induced damage in mouse ovary. Melatonin is a highly effective antioxidant and protects cells against oxidative stress caused by ROS, such as lipid peroxidation and DNA damage [22, 45, 46] . Initially, melatonin was exclusively associated with the reproductive behavior of photosensitive mammals [47] . However, the addition of melatonin to the in vitro culture medium preserved the number of surviving preantral follicles [48] and improved embryonic development [49] in mouse. In addition, the use of melatonin during in vitro culture stimulated the development of caprine secondary follicles [50] and improved oocyte cytoplasmic maturation and subsequent clinical outcomes in women [51] .
A previous study had localized mRNA for MT 1 in mouse granulosa cells from the primary follicle stage onward [20] . However, in the current work, immunostaining for the MT 1 protein was observed in oocytes from all follicle stages, in the granulosa cells from primary, secondary, and antral follicles, and in the theca cells from secondary and antral follicles. Other authors have also demonstrated the MT 1 protein in bovine oocytes [52] and in ovine cumulus oocyte complexes [53] . Although the MT 2 receptor has been described in the ovaries of rat [54] , swine [55] , bovine [56] , and human [57] , we evaluated only the expression of MT 1 because studies have demonstrated that this receptor might be more involved in the regulation of reproductive activity (seasonal reproductive and circadian responses) than the MT 2 receptor [18, 19] . In addition, it was demonstrated that the human MT 2 receptor has a lower affinity for melatonin as compared to the MT 1 receptor [15] . In this sense, it is possible that the physiological involvement of melatonin on mouse folliculogenesis (e.g. follicular survival and oocyte maturation) may be due to its interaction with the MT 1 receptor. However, it would be interesting to evaluate in future experiments whether MT 2 would affect mouse ovarian follicle survival and development.
It is well known that chemotherapeutic agents cause toxic effects on ovarian function [4] . In this study, pretreatment with 20 mg/kg melatonin before cisplatin administration showed more morphologically normal follicles and cell proliferation, reduced apoptosis, increased GSH expression, decreased ROS production, and mitochondrial damage compared to cisplatin treatment alone. Previous reports showed that melatonin is able to scavenge toxic oxygen derivatives and reduce the formation of ROS [58, 59] , stimulate the activities of antioxidant enzymes [45, 60] , and preserve mitochondrial function by reducing electron leakage and protecting the mitochondrial membrane [44, 61] . These actions prevented oxidative stress, thereby inhibiting subsequent apoptotic events and cell death [62, 63] . The pharmacological doses of melatonin used were based on other studies related to the preclinical efficacy of melatonin in reducing chemotherapy-induced toxicity in rodent tissues [34] [35] [36] . However, our results showed that lower melatonin doses (5 or 10 mg/kg) were insufficient to protect the ovaries from cisplatininduced toxic effects. On the other hand, it is worth mentioning that melatonin (20 mg/day) was used as an adjuvant in the chemotherapy of different tumors (lung, gastrointestinal tract, testis, prostate, cervix, and ovarian cancer) improving the rates of tumor regression as well as increasing survival and the quality of life of human cancer patients [64, 65] .
In this study, primordial follicle activation was not observed in any treatment (in both phases I and II). Chang et al. [1] demonstrated that cisplatin (2 mg/kg for 15 days, i.e. total cumulative dose of 30 mg/kg cisplatin) induced overactivation of mouse primordial follicles through the PTEN/AKT/FOXO3 pathway. Nevertheless, ovaries that received 1 mg/kg cisplatin contained follicles in all stages of development after 15 days of treatment (total cumulative dose of 15 mg/kg cisplatin, which is similar to the dose used in this study). Therefore, it seems that the repeated administration of cisplatin for a longer time (15 days), which resulted in a higher final cumulative dose, could induce primordial follicle activation. In another study, mice were pretreated with 30 mg/kg melatonin for 3 days, followed by 2 mg/kg cisplatin and 30 mg/kg melatonin for 15 days. These authors showed that melatonin attenuated primordial follicle loss or overactivation induced by cisplatin, by preventing phosphorylation of the PTEN/AKT/FOXO3 pathway members [11] . Conversely, although follicular activation was not observed in our study, a significant primordial follicle loss was observed, which was probably due to apoptosis related to the acute toxic effect of cisplatin. The mechanisms of chemotherapy-induced ovarian damage have been reviewed by Bedoschi et al. [66] , which highlighted that chemotherapy agents act by causing damage to the DNA, resulting in significant primordial follicle death by apoptosis. In addition, another difference from our study and that of Jang et al. [11] is that they did not evaluate the possible specific intracellular signaling underlying the actions of melatonin on cisplatin-induced cytotoxicity.
Considering that melatonin exerts its anticancer and cytoprotective actions when binding to MT 1 and/or MT 2 receptors [67, 68] , in the current study, the antagonists of these receptors were used to elucidate a potential mechanism by which melatonin could prevent the ovarian damage induced by cisplatin. In this study, pretreatment with the nonselective MT 1 /MT 2 antagonist (luzindole) impaired the chemoprotective effects of melatonin on the morphology, cellular proliferation, apoptosis, ROS levels, and mitochondrial activity damage caused by cisplatin, but not GSH levels. However, when a selective MT 2 antagonist (4-PPDOT) was used, no changes were observed in the evaluated parameters (equal to those results found at 20 mg/kg melatonin). These data and the MT 1 protein expression in mouse ovary highlight the importance of MT 1 receptors in ovarian protection. Similarly, other studies also showed that the MT 1 receptor more frequently regulates tumor proliferation activity than the MT 2 receptor, such as the inhibition of the growth of prostate tumors [69] and the antiproliferative actions of melatonin in breast cancer cells [70] . In addition, luzindole but not 4-PPDOT blocked the antiproliferative effect of melatonin on hormone-refractory human prostate cancer cells, suggesting an MT 1 receptor-mediated effect [71] . Therefore, understanding the actions of melatonin, its receptors, and their Downloaded from https://academic.oup.com/biolreprod/article-abstract/96/6/1244/3862712 by OUP site access user on 15 October 2018 antagonists in the ovary provides a therapeutic potential that should be explored, as new melatonin-like drugs might be developed for preserving ovarian function during chemotherapy.
Finally, treatment with N-acetylcysteine, which is a potent antioxidant and a precursor for GSH production [72] , was used as a positive control. Mice treated with N-acetylcysteine and those from the melatonin group (20 mg/kg) showed similar results in all evaluated parameters, except for GSH levels. In previous studies with rats, 150 mg/kg N-acetylcysteine attenuated the apoptosis of germ and Leydig cells induced by cisplatin via antioxidant pathways [38] . Moreover, N-acetylcysteine blocked the apoptosis of neurons via activation of the P53 signaling pathway and decreased cisplatininduced sensory neuropathy [73] and protected against oxaliplatininduced neurotoxicity [74] . Therefore, these results suggested that melatonin may have potent cytoprotective and antioxidant effects such as N-acetylcysteine.
Taken together, our findings are highly encouraging and it can be concluded from our data that melatonin at 20 mg/kg can be used to protect mouse ovarian follicles during experimental chemotherapy with cisplatin. The immunolocalization of MT 1 receptors in the mouse ovary and the use of melatonin receptors antagonist support the role that MT 1 receptors participate in the mechanism of melatonin action. This effect of melatonin through its receptor may influence the maintenance of follicle morphology and growth (cell proliferation). In addition, melatonin is a scavenger of ROS and has antioxidant effects due to its stimulation of the GSH expression in mouse follicles, thus preserving mitochondrial function and inhibiting subsequent follicle apoptosis (Figure 7 ). This study has also highlighted a promising therapeutic target (the MT 1 receptor), which could be used to promote the development of novel and more efficacious therapeutic agents for preserving ovarian function during chemotherapy. However, future research should address the age-dependent differences in sensitivity to chemotherapy-induced damage to ovary to determine the protective effects of melatonin in cisplatin chemotherapy. To this purpose in vitro culture systems for neonatal, juvenile and prepubertal mouse ovaries could be instrumental. Additionally, it should be evaluated whether pretreatment with melatonin does not interfere with the efficacy of cancer treatment.
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Supplementary data are available at BIOLRE online. Table S1 . Antibodies used for immunohistochemical evaluation in mouse ovaries.
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Supplemental Figure S1 . Immunohistochemical expression of bcl-2 and activated caspase-3 in the different experimental groups from both phases I and II.
